NCT04764422View on ClinicalTrials.gov

Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

March 20, 2021

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions
Covid-19SARS PneumoniaPneumonia, ViralCovid-19 Vaccine
Interventions
BIOLOGICAL

Normal Saline

0.9% normal saline for injection

BIOLOGICAL

NDV-HXP-S vaccine

Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.

Trial Locations (1)

10400

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok

All Listed Sponsors
collaborator

The Government Pharmaceutical Organization

OTHER_GOV

lead

Mahidol University

OTHER

NCT04764422 - Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand | Biotech Hunter | Biotech Hunter